Based on the GlaxoSmithKline PLC ADR stock forecast from 2 analysts, the average analyst target price for GlaxoSmithKline PLC ADR is USD 46.00 over the next 12 months. GlaxoSmithKline PLC ADR’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of GlaxoSmithKline PLC ADR is Bullish , which is based on 11 positive signals and 4 negative signals. At the last closing, GlaxoSmithKline PLC ADR’s stock price was USD 39.27. GlaxoSmithKline PLC ADR’s stock price has changed by -3.75% over the past week, -6.81% over the past month and +6.77% over the last year.
No recent analyst target price found for GlaxoSmithKline PLC ADR
No recent average analyst rating found for GlaxoSmithKline PLC ADR
Company Overview GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom. Read Less
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharma...Read More
Frequently Asked Questions About GlaxoSmithKline PLC ADR (GSK) Stock
Based on ratings from 2 analysts GlaxoSmithKline PLC ADR's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 1 buy, sell and 1 hold ratings.
GSK stock's dividend yield is 3.49%.
Our analysis grades GSK stock's dividend yield at F. This means that GSK stock's dividend yield is above 44% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this GSK may be a average dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for GSK is USD 46.00 over the next 12 months. The maximum analyst target price is USD 48 while the minimum anlayst target price is USD 44.
GSK stock's Price/Earning ratio is 13.87.
Our analysis grades GSK stock's Price / Earning ratio at C+. This means that GSK stock's Price/Earning ratio is above 22% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this GSK may be undervalued for its sector.
The last closing price of GSK's stock was USD 39.27.
The most recent market capitalization for GSK is USD 85.52B.
Based on targets from 2 analysts, the average taret price for GSK is projected at USD 46.00 over the next 12 months.
This means that GSK's stock price may go up by +17.14% over the next 12 months.
We can't find any ETFs which contains GlaxoSmithKline PLC ADR's stock.
As per our most recent records GlaxoSmithKline PLC ADR has 0 Employees.
GlaxoSmithKline PLC ADR's registered address is 980 Great West Road, Brentford, United Kingdom, TW8 9GS.
You can get more information about it from GlaxoSmithKline PLC ADR's website at https://www.gsk.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GSK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
